Clinical Evidence for Intravenous Mesenchymal Stem Cells

The following peer‑reviewed studies and systematic reviews provide the current scientific basis for the use of intravenously administered MSCs in supporting systemic inflammation modulation and tissue homeostasis. All links lead to official sources (PubMed, NIH, Springer).

• Systematic Review & Meta‑Analysis (2023): Intravenous mesenchymal stem cell therapy for inflammatory disorders: a meta‑analysis of randomized controlled trials – Pooled analysis of 18 RCTs (n=876 patients) showing significant reduction in systemic inflammatory markers (CRP, TNF‑α, IL‑6) and improved functional outcomes. (PubMed PMID: 36834058)
• Prospective Clinical Trial (2022): Safety and efficacy of IV umbilical cord MSCs in patients with autoimmune inflammatory conditions (NCT04431869) – Phase I/II trial (n=40) reported no serious adverse events and significant improvement in quality‑of‑life measures at 6 months. (ClinicalTrials.gov identifier: NCT04431869)
• Peer‑Reviewed Original Research (2021): Intravenous allogeneic mesenchymal stem cells for treatment of refractory inflammatory bowel disease – Open‑label study (n=20) demonstrated endoscopic improvement in 65% of patients with concomitant reduction in serum IL‑17 and IFN‑γ. (Stem Cell Research & Therapy, open access)

Study limitation caveat: These studies focused on specific inflammatory conditions (autoimmune disease, inflammatory bowel disease). Applicability to other health concerns (e.g., general wellness, metabolic health, healthy aging) is not established from these studies.

Individual results vary depending on lifestyle and underlying conditions. These studies represent aggregate data; not every patient will experience the same outcomes.

Contraindications & Safety Considerations

The following conditions are absolute or relative contraindications for Stem Cell IV Therapy. A thorough medical evaluation is required before any treatment. This list is not exhaustive.

• Pregnancy & Breastfeeding – Safety has not been established; MSCs may cross the placental barrier.
• Active Malignancy (cancer) – Uncontrolled or recently diagnosed cancer; risk of unintended stimulation.
• Severe Allergies (anaphylaxis history) – Risk of hypersensitivity reaction, especially to infusion components.
• Active Systemic Infection – Including sepsis, bacteremia, or fever of unknown origin.
• Severe Organ Dysfunction – End‑stage renal (eGFR <30), hepatic failure (Child‑Pugh C), or NYHA class IV heart failure.
• Immunosuppressant Medications – High‑dose corticosteroids, chemotherapy, or biologic agents that interfere with MSC function.
• Bleeding Disorders or Anticoagulation – Uncontrolled coagulopathy or therapeutic anticoagulation (unless safely paused).
• Uncontrolled Autoimmune Disease – Flaring lupus, rheumatoid arthritis, multiple sclerosis, etc.

All candidates must complete a comprehensive medical evaluation, including history, physical exam, and relevant laboratory tests, before any stem cell administration.

Adverse Events Frequency

Based on published clinical trials and systematic reviews of intravenous MSC therapy (including studies cited above). Incidence estimates are derived from aggregate data.

Common (>1% incidence) – usually mild to moderate, transient

• Transient fever / low‑grade pyrexia – Approximately 5‑15% of patients, typically resolving within 24‑48 hours.
• Fatigue / lethargy – Reported in 10‑20% of patients, usually lasting 1‑3 days post‑infusion.
• Headache – Occurs in 5‑10% of cases, often responsive to hydration and rest.
• Infusion site reaction – Redness, mild swelling, or tenderness at IV site (2‑5%).
• Nausea – Reported in 3‑8% of patients, typically mild and self‑limited.
• Transient flushing / warmth sensation – 2‑4% during infusion.

Rare serious adverse events (incidence <1% from published data)

• Severe allergic reaction (anaphylaxis) – Isolated case reports; immediate medical intervention required.
• Infection – Contamination during administration (extremely rare under sterile protocols).
• Thromboembolic event – Deep vein thrombosis or pulmonary embolism (single case reports).
• Cytokine release syndrome (CRS) – Theoretical risk; not observed in large trials to date.
• Unanticipated tissue response – Ectopic tissue formation or immunological reaction (no documented cases with UC MSCs).

These frequencies are based on published literature. Individual risk varies with health status. All procedures are performed under licensed physician supervision with emergency protocols in place.

Verify Scientific Research on Our Therapies

The following independent, authoritative sources provide peer‑reviewed literature, clinical trial registries, and regulatory guidelines. You can use them to verify the scientific basis for each product described on this page.

• PubMed (NIH) – Search for mesenchymal stem cell IV research
• ClinicalTrials.gov (NIH) – Registry of MSC clinical trials worldwide
• International Society for Stem Cell Research (ISSCR) – Patient resources on unproven stem cell therapies
• COFEPRIS (Mexican Health Authority) – Official site for regulated health interventions in Mexico
• NIH Stem Cell Information – National Institutes of Health stem cell research portal

These resources are independent and not affiliated with Nexus Stem Cells. They provide objective, evidence‑based information.